AstraZeneca Unloads Four NDAs to ANI Pharmaceuticals in $46.5M Deal Post author:Sam Post published:December 28, 2017 Post category:BioPharma ANI Phamaceuticals funded the acquisitions through a combination of cash and debt. Source: BioSpace You Might Also Like Meet the Little-Known Chinese CAR-T Biotech Up More Than 500% Since June 2017 February 13, 2018 Riboxx Release: Successful Industrial GMP Manufacturing Of RIBOXXIM, A Novel And Highly Potent Toll-Like 3 Ligand For Immunotherapy Of Cancer September 11, 2017 Bay Area's Ardelyx Nabs $160M Deal With Kyowa Hakko Kirin November 27, 2017
Riboxx Release: Successful Industrial GMP Manufacturing Of RIBOXXIM, A Novel And Highly Potent Toll-Like 3 Ligand For Immunotherapy Of Cancer September 11, 2017
